KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Q3 2025 value amounting to $339.7 million.

  • Jazz Pharmaceuticals' Other Operating Expenses rose 2626.85% to $339.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year increase of 6891.32%. This contributed to the annual value of $1.1 billion for FY2024, which is 189.72% up from last year.
  • Jazz Pharmaceuticals' Other Operating Expenses amounted to $339.7 million in Q3 2025, which was up 2626.85% from $1.2 billion recorded in Q2 2025.
  • Jazz Pharmaceuticals' Other Operating Expenses' 5-year high stood at $1.2 billion during Q2 2025, with a 5-year trough of $108.4 million in Q1 2021.
  • For the 5-year period, Jazz Pharmaceuticals' Other Operating Expenses averaged around $353.0 million, with its median value being $283.4 million (2022).
  • Per our database at Business Quant, Jazz Pharmaceuticals' Other Operating Expenses tumbled by 7478.88% in 2021 and then soared by 34648.11% in 2025.
  • Quarter analysis of 5 years shows Jazz Pharmaceuticals' Other Operating Expenses stood at $293.4 million in 2021, then soared by 131.64% to $679.8 million in 2022, then crashed by 59.28% to $276.8 million in 2023, then rose by 3.91% to $287.6 million in 2024, then rose by 18.13% to $339.7 million in 2025.
  • Its Other Operating Expenses stands at $339.7 million for Q3 2025, versus $1.2 billion for Q2 2025 and $287.6 million for Q4 2024.